March 18, 2014Open Access

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Key Points

Key points are not available for this paper at this time.

Abstract

Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant. No new safety signals were observed.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Éric Pujade-Lauraine

Felix Hilpert

B. Weber

Journals

Journal of Clinical Oncology

Actions

Institutions

Université Paris Cité

Centre Antoine Lacassagne

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study